Moderate to Severe Plaque Psoriasis Market New Product Development & Latest Trends

Introduction
Plaque psoriasis is a chronic, immune-mediated inflammatory skin condition that affects more than 125 million people worldwide. While many patients live with mild to moderate disease, those with moderate to severe psoriasis face debilitating symptoms, systemic inflammation, and increased risk of comorbidities such as psoriatic arthritis, cardiovascular disease, diabetes, and depression.

Unlike mild cases typically managed with topicals and phototherapy, moderate to severe psoriasis requires systemic treatment-including oral small molecules and biologic therapies. Over the past 15 years, the therapeutic landscape has been revolutionized by biologic DMARDs targeting TNF-α, IL-12/23, IL-17, and IL-23 pathways, which deliver high rates of skin clearance and durable remission. More recently, JAK inhibitors and TYK2 inhibitors have expanded oral treatment options, giving patients and providers greater flexibility in long-term management.
In 2024, the global moderate to severe plaque psoriasis market is valued at USD 28.64 billion and is projected to reach USD 58.12 billion by 2034, expanding at a robust CAGR of 7.4% (2025-2034).

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71342

Market Overview: Key Highlights
• Market Size (2024): USD 28.64 Billion
• Forecasted Market Size (2034): USD 58.12 Billion
• CAGR (2025-2034): 7.4%
• Largest Region (2024): North America (~46% share)
• Fastest-Growing Region: Asia-Pacific (~8.1% CAGR)
• Leading Therapies: TNF inhibitors, IL-17 and IL-23 inhibitors, TYK2 inhibitors, JAK inhibitors, biosimilars

Growth Drivers: Increasing biologic adoption, pipeline innovation in IL-23 and TYK2 inhibitors, broader reimbursement frameworks, and rising awareness of psoriasis as a systemic disease.
Challenges: High biologic costs, payer step-therapy requirements, biosimilar competition, and adherence issues.

Segmentation Analysis
By Drug Class
• TNF inhibitors: Adalimumab, etanercept, infliximab (established biologics; biosimilars gaining traction).
• IL-12/23 inhibitor: Ustekinumab (dual cytokine targeting).
• IL-17 inhibitors: Secukinumab, ixekizumab, brodalumab (fast skin clearance; strong adoption).
• IL-23 inhibitors: Guselkumab, risankizumab, tildrakizumab (durable remission with convenient dosing).
• JAK/TYK2 inhibitors: Deucravacitinib (TYK2; FDA-approved), tofacitinib and baricitinib (pipeline in psoriasis).
• Other oral systemic agents: Apremilast (PDE4 inhibitor; widely used for moderate disease).
• Emerging therapies: Novel biologics, biosimilars, and small molecules in late-stage pipelines.

By Therapy Type
• Monotherapy (biologic or oral systemic alone).
• Combination therapy (biologic + methotrexate; systemic + topical for residual lesions).

By Technology
• Biologics: Advanced monoclonal antibodies targeting cytokine pathways.
• Small molecules: JAK/TYK2 and PDE4 inhibitors.
• Precision medicine platforms: Biomarker-driven patient stratification.
• Digital dermatology tools: Telehealth, adherence apps, real-world disease monitoring.

By End Use
• Hospitals & dermatology centers (largest segment).
• Specialty clinics (rheumatology overlap with psoriatic arthritis).
• Retail & specialty pharmacies.
• Academic & research institutions.

By Application
• Plaque psoriasis (core market).
• Psoriatic arthritis (comorbidity overlap).
• Special-site psoriasis (scalp, nails, genital, inverse).

Summary:
IL-17 and IL-23 inhibitors are the fastest-growing biologic segments, offering high clearance and long dosing intervals. TYK2 inhibitors are emerging as attractive oral alternatives, particularly for patients unwilling to use injectables.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71342/moderate-to-severe-plaque-psoriasis-market

Regional Analysis
North America
• Largest market (~46% share) due to high biologic adoption, FDA approvals, and strong reimbursement frameworks.
• U.S. drives revenues with broad access to IL-17, IL-23, and TYK2 inhibitors.
• Patient support programs from AbbVie, Novartis, and Johnson & Johnson enhance adherence.
Europe
• Germany, France, the UK, Italy, and Spain dominate the regional market.
• EMA approvals of new biologics and TYK2 inhibitors expanding access.
• Biosimilar competition driving price pressure but broadening access.
Asia-Pacific
• Fastest-growing region (~8.1% CAGR) due to rising diagnosis rates, healthcare modernization, and rapid expansion of biologic availability.
• Japan and South Korea lead in biologic adoption; China and India represent major growth opportunities as reimbursement expands.
Middle East & Africa
• GCC countries (Saudi Arabia, UAE, Qatar) investing in specialty dermatology centers and biologic imports.
• Broader Africa remains reliant on systemic generics and limited biologic access.
Latin America
• Brazil, Mexico, and Argentina dominate, supported by growing public-private reimbursement programs.
• Biosimilars improving affordability and uptake in hospital settings.

Summary:
North America and Europe dominate today's revenues, while Asia-Pacific will be the fastest-growing region due to biosimilar adoption, pipeline expansion, and improving healthcare infrastructure.

Market Dynamics
Key Growth Drivers
1. Biologic Expansion - IL-17 and IL-23 inhibitors delivering superior efficacy and convenience.
2. Oral Innovation - TYK2 inhibitors offering biologic-like efficacy with pill convenience.
3. Pipeline Depth - Strong late-stage development of next-gen biologics and small molecules.
4. Growing Awareness - Recognition of psoriasis as systemic disease driving earlier and aggressive treatment.
5. Reimbursement Frameworks - Broader insurance coverage for biologics in high-prevalence regions.

Key Challenges
1. High Biologic Costs - Payers often enforce step-therapy before biologic initiation.
2. Adherence Issues - Long-term treatment adherence remains variable.
3. Biosimilar Competition - Price pressure and brand loyalty shaping market dynamics.
4. Unequal Access - Limited specialist access in developing regions.

Latest Market Trends
1. Shift Toward IL-23 Dominance - Durable remission and quarterly dosing making IL-23 inhibitors frontline.
2. Oral TYK2 Breakthrough - Deucravacitinib setting a new paradigm for oral therapy.
3. Biologic Biosimilar Uptake - Expanding in Europe and Asia, improving affordability.
4. Teledermatology Growth - Supporting adherence and remote disease monitoring.
5. Comorbidity Management - Psoriatic arthritis overlap fueling cross-specialty biologic adoption.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71754

Competitor Analysis
Major Players
• AbbVie (adalimumab, risankizumab).
• Novartis AG (secukinumab, ixekizumab).
• Johnson & Johnson (Janssen) (ustekinumab, guselkumab).
• Eli Lilly (ixekizumab, baricitinib pipeline).
• Amgen (etanercept, biosimilars).
• Bristol Myers Squibb (deucravacitinib - TYK2 inhibitor).
• Pfizer (tofacitinib - JAK inhibitor research).
• UCB (bimekizumab - IL-17 inhibitor).
• Sun Pharma (apremilast - PDE4 inhibitor).
• Biogen, Samsung Bioepis, Viatris (biosimilars portfolio).
Competitive Landscape:
The market is dominated by biologics, with IL-17 and IL-23 inhibitors leading growth. TYK2 inhibitors are emerging as strong oral competitors. Biosimilars are reshaping pricing dynamics, especially in Europe and Asia, forcing innovators to invest in patient-support programs and real-world evidence generation.

Conclusion
The global moderate to severe plaque psoriasis market is projected to expand from USD 28.64 billion in 2024 to USD 58.12 billion by 2034, at a CAGR of 7.4%.
• North America and Europe dominate current revenues, while Asia-Pacific will deliver the fastest growth.
• IL-17 and IL-23 inhibitors are becoming the preferred biologic options, with TYK2 inhibitors opening new frontiers in oral therapy.
• Biosimilar expansion will improve access but heighten competition.
• Teledermatology and patient-centered care models will enhance adherence and outcomes.
For stakeholders, opportunities lie in scaling IL-23 inhibitors, expanding TYK2 availability, leveraging biosimilars for market penetration, and integrating digital adherence tools. Companies that combine scientific innovation with affordability and patient support will shape the future of psoriasis care through 2034.

This report is also available in the following languages : Japanese (中等度から重度の尋常性乾癬市場), Korean (중등도에서 중증의 플라크 건선 시장), Chinese (中度至重度斑块性银屑病市场), French (Marché du psoriasis en plaques modéré à sévère), German (Markt für mittelschwere bis schwere Plaque-Psoriasis), and Italian (Mercato della psoriasi a placche da moderata a grave), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71342

Our More Reports:

Functional Dyspepsia Market
https://exactitudeconsultancy.com/reports/71114/functional-dyspepsia-market

Exocrine Pancreatic Insufficiency Market
https://exactitudeconsultancy.com/reports/71112/exocrine-pancreatic-insufficiency-market

Crohn's Disease Market
https://exactitudeconsultancy.com/reports/71110/crohn-s-disease-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.